Blogs.fda.gov: August 27, 2012 Parents and guardians of seriously ill children often face difficult decisions about their child’s medical care. As a physician practicing for about 20 years in a pediatric intensive care unit, I knew that many of the interventions I used, while potentially life-saving, had no guarantee of success and carried a risk of […]
Trialsjournal.com: 8/23/12 Adaptive designs allow planned modifications based on data accumulating within a study. The promise of greater flexibility and efficiency stimulates increasing interest in adaptive designs from clinical, academic, and regulatory parties. When adaptive designs are used properly, efficiencies can include a smaller sample size, a more efficient treatment development process, and an increased chance […]
http://ctj.sagepub.com: 8/23/12 Estimating effectiveness of clinical interventions depends on detecting differences between the responses of intervention and control groups. The outcome, intervention, and moderating factors all may influence the between group change. The absence of a clinically or statistically meaningful difference may also result from control group improvement due to nonspecific factors such as participants’ perception […]
bmj.com: 8/21/12 Objectives To investigate the degree to which Cochrane reviews of drug interventions published in 2010 reported conflicts of interest from included trials and, among reviews that reported this information, where it was located in the review documents. Design Cross sectional study. Data sources Cochrane Database of Systematic Reviews. Selection criteria Systematic reviews of drug interventions published in 2010 […]
ctj.sagepub.com: 7/18/12 Background Most Phase II clinical trials utilize a single primary end point to determine the promise of a regimen for future study. However, many disorders manifest themselves in complex ways. For example, migraine headaches can cause pain, auras, photophobia, and emesis. Investigators may believe that a drug is effective at reducing migraine pain and the […]
The U.S. Diabetes Index: Researcher Edition has replaced the Diabetes Atlas. Use this new web-based tool to gain access to maps and charts showing diabetes prevalence, diabetes costs and obesity at the national, state, county, MSA, legislative district and zip code levels. Click here to visit the site
March 15, 2011 Contact: Anne Prince Ph. 202.276.3943 The U.S. Diabetes Index: Mapping the Diabetes Community Measuring Prevalence, Outcomes and Cost WASHINGTON, DC: The National Minority Quality Forum and the Congressional Black Caucus Foundation, in collaboration with the CBC Health Braintrust, is launching the U.S. Diabetes Index (USDI) (www.usdiabetesindex.com)—the national index by which diabetes in the United […]
atvb.ahajournals.org: 9/1/12 Insulin resistance is a characteristic feature of obesity and type 2 diabetes mellitus and impacts the heart in various ways. Impaired insulin-mediated glucose uptake is a uniformly observed characteristic of the heart in these states, although changes in upstream kinase signaling are variable and dependent on the severity and duration of the associated obesity […]
hhs.gov: August 21, 2012. From the U.S. Department of Health and Human Services, I’m Nicholas Garlow with HHS HealthBeat. More people have diabetes now than ever before. People with diabetes often have other health risk factors, like obesity and high blood pressure. But data from the National Health Interview Survey shows that death rates are declining […]
tde.sagepub.com: August 15, 2012. Glucose variability leading to suboptimal glycemic control is common among people using injection therapies. Advanced technology and new studies have identified important issues related to injection technique: needle length and gauge, body mass index, skin and subcutaneous tissue thickness, adequate resuspension of cloudy insulins, leakage, choice of injection site and rotation, pinching […]
 |
